Sign In
Buy IUGNF
$0.0650
-0.0350 (-35.00%)
At Close: Jul 31, 2026
Small Cap Watch: Results come through for several explorers
04:27am, Monday, 08'th Dec 2025
The S&P/ASX Small Ordinaries Index (XSO) closed at 3,670.30, up 16.80 points (0.46%) on Friday, although it remains 1.40% lower over the past five days....
SentinelOne shares drop on weak Q4 guidance, CFO departure
05:35am, Friday, 05'th Dec 2025
SentinelOne (NYSE:S) shares fell 11% in early trade on Friday after the AI-powered cybersecurity firm’s weaker-than-expected guidance and the announcement...
Imugene hits 82% response rate in blood cancer trial - ICYMI
02:04am, Friday, 05'th Dec 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported new clinical data from its Phase 1b trial evaluating azer-cel in patients with diffuse large B-cell lymphoma (DLBCL), including those who ha
Imugene hits 82% response rate in blood cancer trial - ICYMI
08:56pm, Thursday, 04'th Dec 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported new clinical data from its Phase 1b trial evaluating azer-cel in patients with diffuse large...
Imugene lifts response rate to 82% in Phase 1b trial of azer-cel CAR-T therapy
11:56am, Monday, 01'st Dec 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 CAR-T...
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
12:00am, Friday, 28'th Nov 2025
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR
Imugene and JW Therapeutics launch collaborative program to bring CD19 CAR-T innovation to solid tumours
05:22am, Thursday, 27'th Nov 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) has entered a strategic co-development collaboration with JW Therapeutics (Shanghai) Co. LTD (HKEX: 2126) to evaluate a...
Imugene prepares pivotal azer-cel trial with FDA - ICYMI
01:53am, Friday, 07'th Nov 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week provided an update on its cell therapy candidate azer-cel, highlighting strong response rates and upcoming regulatory and scientific milestones. The
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
12:31am, Monday, 14'th Jul 2025
Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1
Imugene activates Australian site for Phase II bowel cancer vaccine trial
09:05pm, Sunday, 01'st Jun 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) has activated its first Australian site in the Phase II Neo-POLEM trial, expanding the clinical investigation of its PD1-Vaxx immunotherapy for a difficult-to-treat fo
Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort
04:09pm, Monday, 15'th Apr 2024
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers,
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
12:00pm, Tuesday, 09'th Apr 2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
10:10am, Thursday, 22'nd Feb 2024
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including
Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
07:57pm, Thursday, 18'th Jan 2024
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
06:30pm, Monday, 11'th Dec 2023
The collaboration will evaluate the ability of NeoImmuneTech's immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing. The combination pot
